Clinically Proven LipoAvail® NAD Better Absorption

Overview

Effepharm

Liposomal technology encapsulates active ingredients within liposomes, mimicking intestinal cell membranes for improved absorption and efficacy.

LipoAvail® NAD+ offers the only clinically validated liposomal NAD+ on the market. Our clinical study shows that the LipoAvail® NAD+ group demonstrated 1.52 times higher NAD+ bioavailability compared to the regular NAD+ group. Meaning more NAD+ can be absorbed by your body for enhanced efficacy!

Download the Liposome White Paper to learn about industry trends; contact us for the study details and discover more clinically backed liposomal products.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Related Topics

IngredientsHealth

Latest Content

Related Resources

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

Paid for by Effepharm Ltd

White Paper

On 11th May 2026, EFSA officially published a positive scientific opinion on EffePharm’s β-NMN as a novel food. This is the first-ever EU official safety endorsement for NMN. UTHEVER® is the 1st NMN ingredient brand to receive EFSA’s positive opinion.

Uthever® NMN: Novel Food Approval Nearing Final Stage

Uthever® NMN: Novel Food Approval Nearing Final Stage

Paid for by Effepharm Ltd

White Paper

One Step Away from EU Market Compliance for NMN. The official positive opinion of Novel Food is expected to be published shortly, which means Uthever® NMN will be the first compliant ingredient.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.